ABC — Abcam Share Price
Last trade - 00:00- £2.88bn
- £3.02bn
- £462.90m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 38.56 | ||
| PEG Ratio (f) | 2.14 | ||
| EPS Growth (f) | 21.96% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.39 | ||
| Price to Tang. Book | 50.45 | ||
| Price to Free Cashflow | 242.06 | ||
| Price to Sales | 6.22 | ||
| EV to EBITDA | 37.04 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.05% | ||
| Return on Equity | 2.68% | ||
| Operating Margin | 5.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 233.2 | 259.9 | 260 | 297.7 | 462.9 | 380 | 429.28 | 16.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +84.8 | -15.35 | -31.45 | -46.31 | +96.46 | +11.08 | +27.79 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Abcam plc is a United Kingdom-based life science company. The Company is engaged in the identification, development and distribution of biological reagents. The Company’s products are used by various researchers worldwide to study biological pathways critical for scientific research, diagnostics and drug discovery. Its products can be grouped into two categories: research use only (RUO) proteomic tools and antibodies for clinical application. RUO products include protein binding reagents, such as antibodies and immunoassays, and related reagents. Its RUO products are used to detect, quantify, visualize and modify proteins in scientific research experiments, serving as vital tools to enable its customers to develop insights about targets and biological pathways of interest. Antibodies are a core component of many in vitro diagnostic assays and can also be used as therapeutic agents to treat various diseases, including cancer.
Directors
- Alan Hirzel CEO
- Michael Baldock CFO (56)
- Marc Perkins GCN
- Mark Capone NED (58)
- Sally Crawford NED (68)
- Chienling Lee NED (55)
- Mara Aspinall NID (58)
- Giles Kerr NID (61)
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- February 12th, 1998
- Public Since
- November 3rd, 2005
- No. of Employees
- 1,750
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 228,978,653
- Address
- Discovery Drive, CAMBRIDGE, CB20AX
- Web
- http://www.abcam.com/
- Phone
- +44 1223696000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ABC
Upcoming Events for ABC
Similar to ABC
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Benchmark Holdings
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 13:00 UTC, shares in Abcam are trading at 1,258.00p. This share price information is delayed by 15 minutes.
Shares in Abcam last closed at 1,258.00p and the price had moved by -15.11% over the past 365 days. In terms of relative price strength the Abcam share price has underperformed the FTSE All Share Index by -15.99% over the past year.
The overall consensus recommendation for Abcam is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Abcam does not currently pay a dividend.
Abcam does not currently pay a dividend.
Abcam does not currently pay a dividend.
To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1,258.00p, shares in Abcam had a market capitalisation of £2.88bn.
Here are the trading details for Abcam:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ABC
Based on an overall assessment of its quality, value and momentum Abcam is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Abcam is 1,483.33p. That is 17.91% above the last closing price of 1,258.00p.
Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of £0.28 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, its share price has underperformed the FTSE All Share Index by -0.8%.
As of the last closing price of 1,258.00p, shares in Abcam were trading -6.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abcam PE ratio based on its reported earnings over the past 12 months is 38.56. The shares last closed at 1,258.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abcam's management team is headed by:
- Alan Hirzel - CEO
- Michael Baldock - CFO
- Marc Perkins - GCN
- Mark Capone - NED
- Sally Crawford - NED
- Chienling Lee - NED
- Mara Aspinall - NID
- Giles Kerr - NID